TMO

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will showcase its latest diagnostic innovations, recent regulatory milestones and expanded capabilities at the Association for Diagnostics & Laboratory Medicine Conference (ADLM), July 26-30, 2026, in Anaheim, Calif. Spanning specialty diagnostics, quality management and the full diagnostic continuum, Thermo Fisher's presence at ADLM 2026 reflects its ongoing commitment to addressing unmet clinic.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific today announced the global launch of Thermo Scientific™ InstaFlux™, an integrated media-on-demand enrichment workflow that helps food microbiology laboratories simplify media preparation, improve productivity and enhance sample traceability. Food testing laboratories face growing pressure to process more samples, meet turnaround expectations and maintain consistent quality while managing staffing constraints, sustainability goals and inc.

Thermo Fisher Scientific NYSE: TMO reported stronger-than-expected second-quarter 2026 results and raised its full-year outlook, citing improving customer activity across end markets, broad-based growth and contributions from recent acquisitions.

Thermo Fisher Scientific Inc. (TMO) Q2 2026 Earnings Call Transcript

Thermo Fisher beats Q2 earnings and revenue estimates as organic growth and stronger customer activity lift results, sending shares higher in pre-market trading.

Although the revenue and EPS for Thermo Fisher (TMO) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Thermo Fisher Scientific (TMO) came out with quarterly earnings of $6.03 per share, beating the Zacks Consensus Estimate of $5.71 per share. This compares to earnings of $5.36 per share a year ago.

Thermo Fisher Scientific beat Wall Street estimates for second-quarter profit and revenue on Thursday, as improving ​customer demand lifted sales across all its business ‌segments.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 27, 2026. Second Quarter Highlights Second quarter revenue grew 10% to $11.99 billion Second quarter GAAP diluted earnings per share (EPS) grew 9% to $4.68 Second quarter adjusted EPS grew 13% to $6.03 “We delivered outstanding performance in the second quarter, reflecting the strength of our proven growth strateg.

ImmuPharma PLC (AIM:IMM, FRA:25I), the drug discovery company, has appointed Thermo Fisher Scientific to develop and manufacture the finished form of its experimental diabetes treatment Kapiglucagon. The US group was chosen after a competitive tender, with its Patheon pharma services arm taking on the drug product workstream.